Overview
Asiri Surgical Hospital operates a specialist private hospital offering surgical, diagnostic and post-operative care. The latest filed quarter showed profit growing faster than revenue as the net margin edged higher, while the preceding annual accounts showed a much lower debt burden and improved ability to meet finance costs.
Price performance
At LKR 10.10 on 7 October 2026, the share had fallen 27.9% over one month, against a 4.8% decline in the ASPI. It closed at its 52-week low, so the valuation is being assessed after a severe retreat rather than near a recent peak.
The record shows four falls of 15% or more in three years, the deepest 63% and not yet recovered. A LKR 1 million order is about 58% of what trades on a typical day, a large part of a day's trading; median daily turnover was LKR 1.7 million, which limits how quickly a meaningful position can be built or exited. Sixty-day volatility was below its own one-year norm, while recent volume ran above its 60-day norm.
Valuation
At 6.3 rupees for every rupee of trailing profit, the P/E is below the healthcare-sector median. The P/B of 0.72 means the market price is 72 cents for each rupee of net assets, also below the sector median; the trailing return on equity was 11.5%, so the discount to book is not explained by a loss-making business.
The company scores 64 of 100 on price against book value, earnings and dividends, placing it in the moderately undervalued band. Its P/B is “the cheapest day in the record since February 2012”, while its P/E is “cheaper than 95% of days since February 2012”. A buyer at this price is relying on a trailing earnings base for which the latest quarter contributed 23.2%, with that quarter's margin only modestly ahead of a year earlier.
There is no current dividend yield and no dividend is on record in the last two years. The latest recorded payout was LKR 0.30 per share for FY2025, so the valuation rests on earnings and asset value rather than income.
News and sentiment
Direct coverage is thin: the 90-day record contains two material articles, both negative. The only supplied item, reported on 17 August 2026, concerned Softlogic Holdings and noted that a tax dispute involving Asiri Surgical Hospital was under appeal; it does not provide terms or a quantified effect on AMSL's earnings.
There are no confirmed or pending corporate actions in the supplied record, and no dividend is on record in the last two years.
Financials
In the June 2026 quarter, revenue rose 7.4% year-on-year to LKR 2.0 billion and net profit rose 11.6% to LKR 226 million. Profit therefore grew faster than the hospital's top line, increasing the earnings attributable to the shares, although the latest quarter was not exceptional on its own June history.
Gross margin was 43.2% versus 43.2% a year earlier, operating margin is unavailable in the latest filing versus 17.3% a year earlier, and net margin was 11.1% versus 10.7%. The gross margin was among its best June readings, ranking 2 of 6 comparable June quarters; net margin ranked 4 of 6, a middling result for that quarter.
For the twelve months to June 2026, revenue grew 6.6% and net margin was 12.6%. The latest audited year to March 2026 had already delivered a 151.6% increase in net profit, but 13.4% of that year's group profit belonged to minority shareholders rather than AMSL ordinary shareholders.
Risks
The leading financial risk is cash generation. In the year to March 2026, operating cash flow was only 0.33 times operating profit and free cash flow was negative LKR 95 million, meaning reported operating profit was not fully arriving as cash after investment spending.
Gearing, meaning debt against owners' equity, was 24.2%, lower than the prior year, and interest cover, meaning operating profit divided by the interest bill, improved to 4.78 times. The current ratio was 1.09, meaning it had LKR 1.09 of short-term assets, including receivables and supplies, for each LKR 1.00 of bills due within a year; this is adequate but leaves limited room if collections weaken.
Healthcare-sector news also highlights greater state involvement in hospital provision and cyber-security exposure. These are sector conditions rather than company-specific events, and the supplied data does not quantify their effect on AMSL.
Outlook
As at 7 October 2026, the next material event is the September 2026 interim-quarter filing, expected between 6 and 14 November. It will show whether the June-quarter combination of revenue growth, stable gross margin and higher net profit continued, and will supersede the figures used in this analysis.
The available data cannot quantify the outcome of the tax appeal mentioned in August reporting, nor does it establish any earnings effect from wider healthcare policy developments. The next filing is therefore the nearer evidence on the operating business, while the appeal remains an unquantified uncertainty.